Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6421 AL 6435

JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities

Mehan S, Meena H, Sharma D, Sankhla R.

J Mol Neurosci. 2011 Mar;43(3):376-90. doi: 10.1007/s12031-010-9454-6. Epub 2010 Sep 28.

Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease

Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, Minthon L, Wallin AK, Andreasen N, Talesa VN, Blennow K.

Acta Neurol Scand. 2011 Aug;124(2):122-9. doi: 10.1111/j.1600-0404.2010.01435.x. Epub 2010 Sep 29.

Physical exercise alleviates debilities of normal aging and Alzheimer's disease

Archer T.

Acta Neurol Scand. 2011 Apr;123(4):221-38. doi: 10.1111/j.1600-0404.2010.01412.x. Epub 2010 Sep 29.

Finding the right target for treating Alzheimer disease

Mandell BF.

Cleve Clin J Med. 2010 Oct;77(10):650. doi: 10.3949/ccjm.77b.10010.

Health economics and health policy issues in Alzheimer's disease

Rapp T.

J Nutr Health Aging. 2010 Oct;14(8):630-2. doi: 10.1007/s12603-010-0308-2.

Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments

McNamee P, Vanoli A, Hutchings D, McKeith I, Bond J.

J Nutr Health Aging. 2010 Oct;14(8):664-8. doi: 10.1007/s12603-010-0313-5.

Phenserine efficacy in Alzheimer's disease

Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH.

J Alzheimers Dis. 2010;22(4):1201-8. doi: 10.3233/JAD-2010-101311.

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

Cappell J, Herrmann N, Cornish S, Lanctôt KL.

CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.

Investigational medications for treatment of patients with Alzheimer disease

Potter PE.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S27-36.

Recruitment of subjects into clinical trials for Alzheimer disease

Knebl JA, Patki D.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S43-9.

Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?

Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B.

Int J Neurosci. 2010 Dec;120(12):746-51. doi: 10.3109/00207454.2010.520381. Epub 2010 Oct 13.

Novel drug targets based on metallobiology of Alzheimer's disease

Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT.

Expert Opin Ther Targets. 2010 Nov;14(11):1177-97. doi: 10.1517/14728222.2010.525352.

[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease]

Wang XH, Yang W, Qi JS.

Sheng Li Xue Bao. 2010 Oct 25;62(5):398-406.

[Molecular targeted therapy in Alzheimer disease]

Morohashi Y, Tomita T, Iwatsubo T.

Nihon Rinsho. 2010 Oct;68(10):1906-10.

Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany

Guo S, Hernandez L, Wasiak R, Gaudig M.

J Med Econ. 2010;13(4):641-54. doi: 10.3111/13696998.2010.528101. Epub 2010 Oct 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias